SLS•November 17, 2026 at 3:09 PM UTCPharmaceuticals, Biotechnology & Life Sciences

SELLAS soars as REGAL Phase 3 topline shows 41% reduction in death risk, validating GPS

Read source article

What happened

SELLAS Life Sciences announced topline results from its pivotal Phase 3 REGAL trial showing galinpepimut-S (GPS) reduced the risk of death by 41% in patients with acute myeloid leukemia in second complete remission, triggering a three-fold surge in the stock to a 52-week high on record volume. The result resolves the key binary event that had dominated the investment thesis since the company disclosed 78 of 80 events in May 2026, with the vaccine now demonstrating a clinically meaningful survival benefit. Despite the positive data, SELLAS remains a development-stage company with no product revenue, $138.3 million in cash as of June 30, 2026, and a market capitalization that has now expanded to roughly $6 billion, implying investors are already pricing in regulatory approval and commercial success. The stock's move reflects unwinding of the speculative overhang that had kept it volatile, as the bear case of a failed or ambiguous readout is largely eliminated, while SLS009's Phase 2 frontline AML study adds a secondary value driver. However, execution risks remain in BLA preparation, manufacturing scale-up, and eventual commercialization, with dilution still a possibility despite the strong balance sheet.

Implication

The 41% reduction in death risk is a meaningful result that likely supports a Biologics License Application (BLA) and potential partnering discussions, shifting the investment case from event-driven speculation to regulatory and commercial execution. With the stock tripling to around $33, the valuation now embeds significant success, with a market cap near $6 billion against no current revenue, meaning further upside requires concrete regulatory milestones and market uptake rather than mere data probability. Cash of $138.3 million provides runway into 2027, but the company may still need additional capital for BLA submission and launch preparation, so dilution risk persists even as financing options improve with positive data. SLS009's ongoing Phase 2 study offers optionality, but its enrollment and data timing remain secondary to the now-validated GPS franchise. Investors should consider trimming into strength if the risk-reward no longer favors holding, as the original thesis based on undervalued optionality has been largely realized.

Thesis delta

The prior 'potential sell' rating rested on uncertainty around the REGAL unblinding; with topline results showing a 41% reduction in death risk, that uncertainty is resolved positively, shifting the thesis to a more constructive stance. The bear case of ineffective or ambiguous data is now largely invalidated, while the bull case of positive efficacy has materialized, though the stock's triple-digit gain likely captures much of the incremental value. The revised view is to hold with a focus on regulatory and commercial milestones, but to be vigilant about overvaluation and dilution risk as the company transitions from clinical-stage to pre-commercial.

Confidence

high